The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis (2022)
Silva, Eduardo Duarte 
; Ulrich, Henning ; Giacomelli, Ágatha Oliveira ; Hartung, Hans Peter ; Meuth, Sven G; Peixoto, Christina Alves
Fonte: Frontiers Immunology. Unidade: IQ
Assuntos: ESCLEROSE MÚLTIPLA, ADENOSINA, RECEPTORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Eduardo Duarte et al. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. Frontiers Immunology, v. 13, p. 1-10 art. 946698, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.946698. Acesso em: 31 out. 2024.APA
Silva, E. D., Ulrich, H., Giacomelli, Á. O., Hartung, H. P., Meuth, S. G., & Peixoto, C. A. (2022). The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. Frontiers Immunology, 13, 1-10 art. 946698. doi:10.3389/fimmu.2022.946698NLM
Silva ED, Ulrich H, Giacomelli ÁO, Hartung HP, Meuth SG, Peixoto CA. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis [Internet]. Frontiers Immunology. 2022 ; 13 1-10 art. 946698.[citado 2024 out. 31 ] Available from: https://doi.org/10.3389/fimmu.2022.946698Vancouver
Silva ED, Ulrich H, Giacomelli ÁO, Hartung HP, Meuth SG, Peixoto CA. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis [Internet]. Frontiers Immunology. 2022 ; 13 1-10 art. 946698.[citado 2024 out. 31 ] Available from: https://doi.org/10.3389/fimmu.2022.946698
